Aprea Therapeutics Inc (APRE) — Cash Flow-to-Debt Ratio
Aprea Therapeutics Inc (APRE) has a Cash Flow-to-Debt Ratio of -0.52x as of March 2026, meaning its operating cash flow of $-2.76 Million could theoretically repay -1% of its total liabilities ($5.30 Million) in one year. Explore how efficiently does Aprea Therapeutics Inc generate cash to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aprea Therapeutics Inc Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for Aprea Therapeutics Inc across 10 annual periods. Also explore APRE asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Aprea Therapeutics Inc (2007–2025)
Year-by-year debt coverage analysis for Aprea Therapeutics Inc. For market capitalisation and broader financial context, see APRE company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.69x | $-12.89 Million | $3.49 Million | ▼ -27.3% |
| 2024 | -2.90x | $-13.56 Million | $4.67 Million | ▼ -4.5% |
| 2023 | -2.78x | $-12.18 Million | $4.39 Million | ▲ +49.9% |
| 2022 | -5.54x | $-25.01 Million | $4.51 Million | ▼ -7.6% |
| 2021 | -5.15x | $-37.69 Million | $7.32 Million | ▼ -89.9% |
| 2020 | -2.71x | $-41.80 Million | $15.41 Million | ▲ +4.9% |
| 2019 | -2.85x | $-26.71 Million | $9.36 Million | ▼ -2096.8% |
| 2018 | -0.13x | $-15.25 Million | $117.46 Million | ▲ +43.9% |
| 2017 | -0.23x | $-14.00 Million | $60.53 Million | ▲ +70.4% |
| 2007 | -0.78x | $-1.90 Million | $2.43 Million | — |